Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials
- PMID: 35325623
- DOI: 10.1016/S2468-1253(22)00007-3
Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials
Abstract
Perianal fistulising Crohn's disease is an aggressive disease phenotype that can have a substantial detrimental impact on patients' quality of life. Current biological understanding of perianal fistulising Crohn's disease remains inadequate and previous classification systems have not provided clear guidance on therapy in clinical practice nor on defining patient cohorts within clinical trials. We propose a new classification system for perianal fistulising Crohn's disease that was developed through a modified nominal group technique expert consensus process. The classification identifies four groups of patients. Key elements include stratification according to disease severity as well as disease outcome; synchronisation of patient and clinician goals in decision making, with a proactive, combined medical and surgical approach, on a treat to patient goal basis; and identification of indications for curative fistula treatment, diverting ostomy, and proctectomy. The new classification retains an element of flexibility, in which patients can cycle through different classes over time. Furthermore, with each specific class comes a paired treatment strategy suggestion and description of clinical trial suitability. The proposed classification system is the first of its kind and is an important step towards tailored standardisation of clinical practice and research in patients with perianal fistulising Crohn's disease.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests JG has served as an advisory board member or speaker for Arena and Janssen. NI is funded by a Royal College of Surgeons research fellowship, sponsored by the Ileostomy & Internal Pouch Association. JFL has served as a speaker for Janssen. SA is supported through an Australian Government Research Training Program Scholarship. CJB has an unrestricted grant from Boehringer Ingelheim and Roche, and has received speaker fees from Takeda, Tillotts, and Galapagos. KBG has received grants from Pfizer Inc and Celltrion; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, ImmunicTherapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, and Takeda, and speaker's honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda, and Tillotts. ALL has served as a consultant for Takeda. SD reports consultancy fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, TiGenix, UCB Inc, and Vifor. AS has served as speaker for Takeda, Johnson and Johnson, and Pfizer. MC has served as speaker for Pfizer. AD'H has served as speaker for Johnson & Johnson and Takeda. SV has received grants from AbbVie, J&J, Pfizer, and Takeda; and has received consulting and/or speaking fees from AbbVie, Arena Pharmaceuticals, Avaxia, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, Hospira, Janssen, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Takeda, Theravance, and Tillots Pharma AG. AH has served as consultant, advisory board member or speaker for AbbVie, Arena, Atlantic, Bristol-Myers Squibb, Celgene, Celltrion, Falk, Ferring, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire, and Takeda, and serves on the global steering committee for Genentech. PT has acted as speaker and/or served on advisory boards for Takeda and Ferring. All other authors declared no competing interests.
Similar articles
-
Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs.J Crohns Colitis. 2016 Jul;10(7):758-65. doi: 10.1093/ecco-jcc/jjw039. Epub 2016 Jan 28. J Crohns Colitis. 2016. PMID: 26826183
-
External validation of the MAGNIFI-CD index in patients with complex perianal fistulising Crohn's disease.Eur Radiol. 2025 Mar;35(3):1428-1439. doi: 10.1007/s00330-024-11029-3. Epub 2024 Aug 30. Eur Radiol. 2025. PMID: 39212672 Free PMC article.
-
Perianal Fistulizing Crohn's Disease: Utilizing the TOpClass Classification in Clinical Practice to Provide Targeted Individualized Care.Clin Gastroenterol Hepatol. 2025 May;23(6):914-926. doi: 10.1016/j.cgh.2024.06.047. Epub 2024 Aug 10. Clin Gastroenterol Hepatol. 2025. PMID: 39134293 Review.
-
Pathogenesis of Perianal Fistulising Crohn's Disease: Current Knowledge, Gaps in Understanding, and Future Research Directions.J Crohns Colitis. 2023 Jun 16;17(6):1010-1022. doi: 10.1093/ecco-jcc/jjad008. J Crohns Colitis. 2023. PMID: 36655753 Review.
-
TOpCLASS Expert Consensus Classification of Perianal Fistulising Crohn's Disease: A Real-world Application in a Serial Fistula MRI Cohort.J Crohns Colitis. 2024 Sep 3;18(9):1430-1439. doi: 10.1093/ecco-jcc/jjae056. J Crohns Colitis. 2024. PMID: 38642332 Free PMC article.
Cited by
-
Causal Link between Inflammatory Bowel Disease and Fistula: Evidence from Mendelian Randomization Study.J Clin Med. 2023 Mar 24;12(7):2482. doi: 10.3390/jcm12072482. J Clin Med. 2023. PMID: 37048564 Free PMC article.
-
Perianal fistulizing Crohn's disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies.Indian J Gastroenterol. 2024 Feb;43(1):48-63. doi: 10.1007/s12664-024-01524-2. Epub 2024 Feb 3. Indian J Gastroenterol. 2024. PMID: 38308773 Review.
-
Quaternized Molecular Brush-Grafted Injectable Microgel with Anti-Inflammatory and Drainage Properties for Efficient Therapy of Anal Fistula.Adv Sci (Weinh). 2025 Feb;12(5):e2407537. doi: 10.1002/advs.202407537. Epub 2024 Dec 9. Adv Sci (Weinh). 2025. PMID: 39651807 Free PMC article.
-
Clinical relevance of calprotectin in patients with perianal fistulas in Crohn's disease and cryptoglandular fistulas.United European Gastroenterol J. 2025 Apr;13(3):295-304. doi: 10.1002/ueg2.12622. Epub 2024 Dec 16. United European Gastroenterol J. 2025. PMID: 39680482 Free PMC article.
-
Early diagnosis of Crohn's disease in patients presenting with a perianal fistula: systematic review and development of a perianal red flags index.Tech Coloproctol. 2025 Mar 28;29(1):89. doi: 10.1007/s10151-024-03106-y. Tech Coloproctol. 2025. PMID: 40155532 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical